Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.
Cody OrrWenjie XuHenry MasurShyam KottililEric G MeissnerPublished in: BMC infectious diseases (2020)
Patients who relapse after hepatitis C virus therapy differ immunologically from non-relapsers based on expression of transcripts related to interferon signaling and T-cell dysfunction, as well as by peripheral neutrophil and NK-cell concentrations. These data provide insight into the host immunologic basis of relapse after DAA therapy for HCV and suggests mechanisms which may be relevant for understanding outcomes with currently approved regimens.
Keyphrases
- hepatitis c virus
- peripheral blood
- human immunodeficiency virus
- free survival
- nk cells
- poor prognosis
- oxidative stress
- electronic health record
- dendritic cells
- hiv infected
- big data
- stem cells
- antiretroviral therapy
- type diabetes
- bone marrow
- combination therapy
- immune response
- adipose tissue
- metabolic syndrome
- machine learning
- long non coding rna
- mesenchymal stem cells
- skeletal muscle
- replacement therapy
- drug administration